Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer (Q45361593)
Jump to navigation
Jump to search
scientific article published on 12 November 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer |
scientific article published on 12 November 2013 |
Statements
1 reference
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer (English)
1 reference
Manfred Welslau
Veronique Diéras
Sara A Hurvitz
Deepa Lalla
Liang Fang
Betsy Althaus
Ellie Guardino
12 November 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference